These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25018911)

  • 1. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.
    Bover J; Cozzolino M
    Kidney Int Suppl (2011); 2011 Sep; 1(4):122-129. PubMed ID: 25018911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes.
    Ronco C; Cozzolino M
    Heart Fail Rev; 2012 Mar; 17(2):211-20. PubMed ID: 21327712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D; Bommer J; Coyne D
    Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
    Andress DL
    Kidney Int; 2006 Jan; 69(1):33-43. PubMed ID: 16374421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring the physiology of vitamin D receptor activation and the concept of selectivity.
    Cozzolino M; Brenna I; Volpi E; Ciceri P; Mehmeti F; Cusi D
    Contrib Nephrol; 2011; 171():151-156. PubMed ID: 21625104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of paricalcitol on left ventricular hypertrophy.
    Cozzolino M; Ronco C
    Contrib Nephrol; 2011; 171():161-165. PubMed ID: 21625106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
    Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor and analogs.
    Dusso AS; Thadhani R; Slatopolsky E
    Semin Nephrol; 2004 Jan; 24(1):10-6. PubMed ID: 14730505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.